Latest Breaking News On - Molecular subtypes - Page 3 : comparemela.com

Geron Corporation: Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Company s first-in-class telomerase inhibitor, will be made at the European Hematology Association (EHA) Annual Congress meeting to be held virtually from June 9 17. The abstracts for the posters are available on the EHA website at www.ehaweb.org. Both posters will be published on the EHA Virtual Congress platform on June 11, 2021. We are pleased that the EHA accepted both of our abstracts which allows us to present what we believe to be imetelstat s compelling potential to become a leading treatment for lower risk MDS and MF patients, said Aleksandra Rizo, M.D., Ph.D., Geron s Chief Medical Officer. The new data and analyses from our Phase 2 IMbark and IMerge trials continue to h

United statesAleksandra rizoExchange commissionDrug administrationGeron corporation nasdaqEuropean hematology associationVirtual congressGeron corporationAnnual congressChief medicalMolecular subtypesHeavily transfused non delLower riskErythropoiesis stimulating agentsImetelstat demonstratesAcceptable safety profile